The company's adaptive low-resource testing technology requires no instrumentation and limited equipment, making it adaptable to settings without clinical lab infrastructure.
The company said that it will use the funds to build out its CLIA facility and continue developing its blood-based Alzheimer's disease test for the clinic.
The findings suggest blood-based testing for tau brain deposits is feasible and could be combined with other blood-based assays to improve Alzheimer's testing.
The company will offer a 32-gene polygenic score test to patients in the Osaka, Japan Nakanoshima Clinic, with reporting and patient support help from IxLayer.
The company said its sample preparation technology uses nanomagnetic particles that can reduce the effects of complex interferences in patient samples.
Such an approach could be more specific for Alzheimer's than symptoms-based diagnoses while also allowing for earlier detection and treatment of the condition.
